Phage-EV Conjugates: Healing Chronic Wounds and Infections
Novel Bioactive Nano-constructs for Treatment of Chronic Wound Infections
Tags: The University of Sydney, Australia, Healthcare & Lifesciences, Agriculture & Food
This innovation introduces a novel phage-extracellular vesicle (EV) conjugate designed to combat bacterial infections while promoting tissue repair, especially for chronic wounds and diabetes-related injuries. The conjugate enables targeted therapeutic action, combining antimicrobial activity, inflammation reduction, and tissue regeneration, making it a comprehensive solution for resistant infections. Applications include treating diabetic foot ulcers, orthopedic implant complications, and other chronic wound infections. The technology also supports customization for various pathogens and therapeutic agents, enhancing its adaptability. Protected by a provisional patent, it offers significant potential for healthcare, food science, agriculture, and veterinary applications.
IP Type or Form Factor: Patent Pending; Material; Platform
TRL: 3 - proof of concept with needs validated
Industry or Tech Area: Biotechnology; Agriculture
